Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy individuals as controls. Peripheral blood samples were collected from newly diagnosed pancreatic cancer patients and healthy individuals. Using techniques such as plasma TCR/BCR-seq, CyTOF, and plasma proteomics, multi-modal individual immune characteristics were obtained and analyzed along with clinical information. An artificial intelligence predictive model was built based on these multi-modal individual immune characteristics to establish an early screening technique for pancreatic cancer. The sensitivity and specificity of this artificial intelligence model for early pancreatic cancer diagnosis were evaluated using an external multicenter sample test set.
Sign the informed consent form;
Initial diagnosis as patients with pancreatic cancer, patients with benign pancreatic lesions, or healthy controls.
History of other malignancies;
Presence of organ dysfunction;
Concurrent immunodeficiency syndrome, active tuberculosis, HIV infection, etc.;
Allogeneic transplantation requiring immunosuppressive therapy;
Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy individuals as controls. Peripheral blood samples were collected from newly diagnosed pancreatic cancer patients and healthy individuals. Using techniques such as plasma TCR-seq, CyTOF, and plasma proteomics, multi-modal individual immune characteristics were obtained and analyzed along with clinical information. An artificial intelligence predictive model was built based on these multi-modal individual immune characteristics to establish an early screening technique for pancreatic cancer.
Cohort
Prospective
Not listed
Peripheral blood mononuclear cell
Using RNA seq technology to analyze differentially expressed genes in peripheral immune cells
Peripheral blood mononuclear cell
TCR/BCR-seq:Using multiple amplification to obtain the CDR3（complementarities determining region3） region of TCR and BCR and analyzing the VDJ rearrangement pattern
Peripheral blood mononuclear cell
Analyzing RNA expression in individual cells using scRNA-seq
Peripheral blood mononuclear cell
scTCR/BCR-seq:Using multiple amplification to obtain the CDR3（complementarities determining region3） region of TCR and BCR and analyzing the VDJ rearrangement pattern in individual cells
Click on the lead sponsor to view all of their trials.
Zhejiang University
Lead sponsor
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Collaborator
Nanjing Medical University
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
